Evidence map›Paper›PMID 28356850›Full record

ArticleJournal of medical biochemistry2015

Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis.

Ivan Jančić, Mirjana Šefik-Bukilica, Slađana Živojinović, Nemanja Damjanov, Vesna Spasovski, Nikola Kotur, Kristel Klaassen, Sonja Pavlović, Biljana Bufan, Nevena Arsenović-Ranin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Can Pharmacogenetic Variants inInternational journal of molecular sciences · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Journal of medical biochemistry · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ivan JančićDepartment of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Mirjana Šefik-BukilicaInstitute of Rheumatology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Slađana ŽivojinovićInstitute of Rheumatology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Nemanja DamjanovInstitute of Rheumatology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Vesna SpasovskiInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Nikola KoturInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Kristel KlaassenInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Sonja PavlovićInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Biljana BufanDepartment of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Nevena Arsenović-RaninDepartment of Microbiology and Immunology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe study was undertaken to assess the influence of functional -308G/A TNF-α (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-α blocker, in patients with rheumatoid arthritis (RA).

methodsSeventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-α and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed.

resultsNo difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-α-308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/TNF-α genotypes showed that patients with the IL-6 -174GG / TNF-α-308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-α-308GG genotype were responders after 12 months of etanercept treatment.

conclusionsThe study suggests that patients who are genetically low TNF-α and IL-6 producers are the best responders to etanercept therapy.

Indexed as

-174G/C IL-6 gene polymorphism-308G/A TNF-α gene polymorphismetanerceptpharmacogeneticsrheumatoid arthritis

Identifiers

PMID28356850
PMCPMC4922353
OpenAlexW2015746173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.